Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

CSL Behring Announces 2014 Gettin’ in the Game Winners

CSL Behring’s Gettin’ in the Game program, like our FitFactor program, encourages patients with hemophilia, von Willebrand disease (vWD), and other bleeding disorders to become active and stay active, touting the physical and mental benefits of sports and other activities. Recently, CSL Behring held their 13th Junior National Championship program, an annual golf and baseball […]

Industry News

PPTA: Ebola Virus and Plasma Protein Therapies

The recent outbreak of Ebola virus has caused great concern among many people. We read stories about isolation, experimental therapies and many deaths. It is understandable that this raises questions for persons who are more vulnerable to infections such as persons with immunedeficencies. We have seen questions and concerns expressed by various persons and would […]

Industry News

Biogen and MicroHealth Launch Digital Health App

Micro8 is a secure application that may help the Hemophilia A community manage infusion schedules and track bleeding episodes, and may help clinicians stay updated on their patients’ care. Micro8 provides mobile app, text- messaging and web-based tracking options for individuals and caregivers, who have historically logged infusions and bleeding episodes on paper or have […]

Industry News

Grifols Launches Higher Potency Alphanate

Grifols, a leader in the production of plasma-derived medicines, announces the launch of a 2000 IU/vial assay size for ALPHANATE. ALPHANATE is indicated for the control and prevention of bleeding in patients with Hemophilia A and for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease in whom desmopressin (DDAVP) is […]

Industry News

RIXUBIS Approved for Treatment of Children with Hemophilia B

Baxter International Inc. announced on Monday, September 15 that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX (rFIX) approved for routine prophylaxis and […]

industry_news_fb

Baxter Announces Name Change to Baxalta

Baxter International Inc. announced on Wednesday, September 10, 2014 that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015. Upon completion of the separation, Baxalta plans to trade on the New York Stock Exchange (NYSE) under the symbol BXLT. Baxter International will continue trading […]

Industry News

Baxter Reports Success in Long-Acting Hemophilia Product

This article was originally published in Reuters on August 21, 2014. Click here to read it in its entirety. ______________________ Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study. The experimental drug, BAX 855, was being tested as a preventive therapy […]

Medical research

EU Gives Hemophilia Sub-Q Injection Orphan Drug Designations

Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin […]

Industry News

Octapharma’s Hemophilia A Product Approved in Europe

The European Commission has published approval of Octapharma’s Nuwiq ® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with hemophilia A (congenital factor VIII [FVIII] deficiency). Nuwiq ® is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin. Nuwiq […]

Industry News

Pfizer: Phase 3 Study Postitive Results of Weekly Prophylaxis

Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment _____________________________ Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the […]

Page 5 of 1812345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community